<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">High Blood Press Cardiovasc Prev</journal-id><journal-id journal-id-type="iso-abbrev">High Blood Press Cardiovasc Prev</journal-id><journal-title-group><journal-title>High Blood Pressure &#x00026; Cardiovascular Prevention</journal-title></journal-title-group><issn pub-type="ppub">1120-9879</issn><issn pub-type="epub">1179-1985</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27339779</article-id><article-id pub-id-type="pmc">5315731</article-id><article-id pub-id-type="publisher-id">163</article-id><article-id pub-id-type="doi">10.1007/s40292-016-0163-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Cicero</surname><given-names>Arrigo Francesco Giuseppe</given-names></name><address><phone>++39 512142224</phone><email>arrigo.cicero@unibo.it</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Colletti</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fogacci</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bove</surname><given-names>Marilisa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rosticci</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Borghi</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1758</institution-id><institution-id institution-id-type="GRID">grid.6292.f</institution-id><institution>Department of Medicine and Surgery Sciences, </institution><institution>University of Bologna, </institution></institution-wrap>Bologna, Italy </aff><aff id="Aff2"><label>2</label>Hypertension Research Center, Poliambulatorio Pad. 2, Via Albertoni, 15, 40138 Bologna, Italy </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>24</volume><issue>1</issue><fpage>13</fpage><lpage>18</lpage><history><date date-type="received"><day>7</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>There is an increasing interest for combined nutraceuticals that can act on several points of lipid and glucose metabolism with preventive purposes. However, the simple assemblage of nutraceuticals with potentially additive mechanism of action need to be clinically tested.</p></sec><sec><title>Methods</title><p>To assess the effects of a combination of nutraceuticals based on artichoke, red yeast rice, banaba, and coenzyme Q10, we performed a double bind, cross-over designed trial versus placebo in 30 adults with LDL cholesterol suboptimal in primary prevention of cardiovascular disease. After a period of 3&#x000a0;weeks of dietary habits correction, patients began a period of 6&#x000a0;weeks of treatment with nutraceutical or placebo, followed by 2&#x000a0;weeks of washout and finally 6&#x000a0;weeks in cross-over. Data related to lipid pattern, insulin resistance, renal function, liver and CPK have been obtained at each visit.</p></sec><sec><title>Results</title><p>In particular, the after the nutraceutical treatment the enrolled patients experienced a significant improvement in total cholesterol (&#x02212;13.6&#x000a0;%), LDL-C (&#x02212;18.2&#x000a0;%), non-HDL-C (&#x02212;15&#x000a0;%), glutamic oxaloacetic transaminase (&#x02212;10&#x000a0;%), glutamate-pyruvate transaminase (&#x02212;30.9&#x000a0;%), and hs-CRP (&#x02212;18.2&#x000a0;%) versus placebo. No changes have been observed in the other investigated parameters in both groups.</p></sec><sec><title>Conclusions</title><p>The tested combination of nutraceuticals has shown clinical efficacy in the reduction of total cholesterol, non-HDL, LDL and triglycerides, while improving the level of liver transaminases and high sensitivity C-reactive protein. Further confirmation are needed to verify these observations on the middle and long term with a larger number of subjects.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nutraceuticals</kwd><kwd>Monacolin K</kwd><kwd>Insulin-sensitivity</kwd><kwd>Dyslipidemia</kwd><kwd>Artichoke</kwd><kwd>Banaba</kwd><kwd>Coenzyme Q10</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e0; di Bologna (IT)</institution></funding-source><award-id>RFO2015</award-id><principal-award-recipient><name><surname>Cicero</surname><given-names>Arrigo Francesco Giuseppe</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Cardiovascular disease is the leading cause of death in the developed countries. The main risk factors, evaluated by the INTERHEART case&#x02013;control study, are dyslipidemia, smoking, psychosocial factors, diabetes and hypertension [<xref ref-type="bibr" rid="CR1">1</xref>]. In particular, dyslipidemia is considered the principle modifiable risk factor, because of its role in the development of atherosclerosis and clinical events [<xref ref-type="bibr" rid="CR2">2</xref>]. Guidelines for dyslipidemia management suggest a treatment that include lifestyle modification and pharmacotherapy based on identification of groups considered at high, medium or low risk of major cardiovascular events [<xref ref-type="bibr" rid="CR3">3</xref>]. Nevertheless, lifestyle changes are not always sufficient to reach desirable cholesterol levels, in particular in high-risk subjects, but also in low risk patients that have sub-optimal lipid parameters.</p><p>Nutraceuticals are borderline devices between nutrients and drugs providing a supplementation of particular nutrients with beneficial effects on health. More than 40 nutraceutical substances have been studied in order to improve lipid metabolism and some clinical trials demonstrated a cholesterol lowering activity, an improvement of glucose metabolism and inflammatory parameters, besides a possible positive influence on cardiovascular prognosis [<xref ref-type="bibr" rid="CR4">4</xref>]. Among them, red yeast rice, artichoke, banaba and coenzyme Q10 showed interesting results.</p><p>Red yeast rice is a nutraceutical produced by fermenting white rice with the yeast, <italic>Monascus purpureus</italic>. Its content in monacolins is responsible of its lipid-lowering properties, by the inhibition of hydroxymethylglutaryl-coenzyme A reductase, the rate limiting step in cholesterol synthesis. Many clinical trials have found red yeast rice effective at improving the lipid profile. It has also been used as an alternative to drugs in patients with mild to moderate hypercholesterolemia and in subjects intolerant to statin therapy due to statin-associated myalgia. Furthermore, a large randomized controlled study significantly showed that the intake of red yeast rice improve the risk of major adverse cardiovascular events and overall survival in patients following myocardial infarction [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>The artichoke (<italic>Cynara scolymus</italic>) inhibits cholesterol biosynthesis [<xref ref-type="bibr" rid="CR6">6</xref>] and of low-density lipoprotein (LDL) oxidation, improving endothelial function [<xref ref-type="bibr" rid="CR7">7</xref>]. Moreover, clinical studies have shown also choleretic, hepatoprotective [<xref ref-type="bibr" rid="CR8">8</xref>] and glucose lowering activity [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>
<italic>Lagerstroemia speciosa</italic>, commonly known as&#x000a0;banaba, is a tropical plant found in many parts of South-East Asia. In the Philippines, the dried and shredded banaba leaves are used as a treatment for diabetes and kidney disease. Many studies in vivo and in vitro confirmed the antidiabetic activity of banaba, due to both corosolic acid as well as ellagitannins [<xref ref-type="bibr" rid="CR10">10</xref>]. The mechanisms of action involved include enhanced cellular uptake of glucose, impaired hydrolysis of sucrose and starches, decreased gluconeogenesis and the regulation of lipid metabolism. These activities can be mediated by peroxisome proliferator-activated receptor (PPAR), mitogen-activated protein kinase (MAP K), NF-&#x003ba;B and other signal transduction factors. The supplementation with banaba has demonstrated to be safe and well tolerated in clinical trials [<xref ref-type="bibr" rid="CR11">11</xref>]. Moreover, its action on both lipid and glucose metabolism make banaba a potential useful tool also in the management of metabolic syndrome [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Coenzyme Q10 (CoQ10) is a naturally occurring component present in living cells. The potential use of coenzyme Q10 supplements may help prevent or treat some pathologies, in particular cardiovascular diseases, high blood pressure, obesity and diabetes. It acts as an essential cofactor for ATP production and to perform important antioxidant activities in the body [<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, it inhibits LDL oxidation and thus the progression of atherosclerosis. It decreases pro-inflammatory cytokines and decreases blood viscosity, which could be useful in subjects with heart failure and coronary artery disease [<xref ref-type="bibr" rid="CR14">14</xref>]. This is important because low-grade inflammation and oxidative stress are the key factors in the pathogenesis and development of atherosclerosis and its complications [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>The association of more nutraceuticals has demonstrated a synergistic effects, in particular in patients that present two or more risk factors for cardiovascular diseases [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>This clinical trial has the aim to test the effectiveness and safety of a combination of red yeast rice, artichoke, banaba and coenzyme Q10 on glucose metabolism, lipid pattern and inflammatory parameters in hypercholesterolemic patients.</p></sec><sec id="Sec2"><title>Materials and Methods</title><sec id="Sec3"><title>Study Design</title><p>This double blind, placebo-controlled, randomized clinical trial was carried out in 40 moderately hypercholesterolemic patients with metabolic syndrome, in primary prevention for cardiovascular diseases, consecutively enrolled in the ambulatory service of cardiovascular disease prevention in the Medical and Surgical Sciences Department of the University of Bologna.</p><p>The study was a cross-over designed trial of 18&#x000a0;weeks, preceded by 3&#x000a0;weeks of diet stabilization in which patients received standard behavioural and qualitative (not quantitative) dietary suggestions to correct unhealthy habits. In particular, subjects were instructed to follow a general indication of a Mediterranean diet, avoiding excessive intake of dairy products and red meat derived products during the study, and maintaining overall constant dietary habits. Individuals were also generically encouraged to increase their physical activity by walking briskly for 20&#x02013;30&#x000a0;min, 3&#x02013;5 times per week, or by cycling.</p><p>Inclusion criteria were:<list list-type="bullet"><list-item><p>age between 25 and 75</p></list-item><list-item><p>LDL-cholesterol (LDL-C) level between 130 and 190&#x000a0;mg/dL</p></list-item><list-item><p>Body mass index (BMI) value between 25 and 30&#x000a0;kg/m<sup>2</sup>
</p></list-item><list-item><p>Triglycerides (TG) level between 150 and 400&#x000a0;mg/dL</p></list-item><list-item><p>Fasting plasma glucose (FPG) level under 125&#x000a0;mg/dL.</p></list-item><list-item><p>When present, assumption of lipid-lowering or antihypertensive drugs stabilized since at least 6&#x000a0;months.</p></list-item></list>
</p><p>Exclusion criteria were:<list list-type="bullet"><list-item><p>secondary prevention for cardiovascular diseases</p></list-item><list-item><p>assumption of antidiabetic drugs</p></list-item><list-item><p>inconstant or not-stabilized assumption of drugs which may interfere with lipid or glucose metabolism</p></list-item><list-item><p>chronic gastrointestinal diseases and assumption of drugs for their treatment</p></list-item><list-item><p>known thyroid, liver, renal or muscle diseases</p></list-item><list-item><p>known allergy or intolerance to a component of the tested product</p></list-item><list-item><p>any medical or surgical condition which could lead to an inconstant adhesion to the protocol.</p></list-item></list>
</p><p>The study was fully conducted in accordance with the Declaration of Helsinki, its protocol was approved by the Ethical Committee of the University of Bologna, and informed consent was obtained from all patients before the inclusion in the study.</p></sec><sec id="Sec4"><title>Treatments</title><p>After 4&#x000a0;weeks of diet and physical activity stabilization, patients were allocated to treatment with an indistinguishable pill of placebo or with an active product containing 500&#x000a0;mg of artichoke extract, 200&#x000a0;mg of red yeast rice (corresponding to 10&#x000a0;mg of monacolin K), 75&#x000a0;mg of banaba extract, 50&#x000a0;mg of coenzyme Q10, 9&#x000a0;mg of vitamin B3, 1.4&#x000a0;mg of vitamin B6, 0.83 mcg of vitamin B12, 110&#x000a0;mcg of folic acid, kindly offered by Named SpA (Lesmo, Italy).</p><p>After 6&#x000a0;weeks of treatment (or placebo), patients were asked to observe a 2-week washout period, and they were then assigned to the alternative treatment for a further period of 6&#x000a0;weeks. Clinical and laboratory data have been obtained at the baseline, at the end of the first treatment period, after the washout, and again after the second treatment period.</p><p>Randomization was done assigning an alphabetical code to each lot code (corresponding to treatment or placebo) impressed on the pillbox. Codes were then kept in a sealed envelope, which was not opened until the end of the trial. Pillboxes were then mixed, and the investigators assigned a blinded pillbox to each enrolled patient.</p><p>Throughout the study, we instructed patients to take the product first dose on the day after they were given the study product. At the same time, all unused products were retrieved to the investigator.</p></sec><sec id="Sec5"><title>Assessments</title><p>Personal data, CVD history and pharmaceutical anamnesis of each patient were inquired at the beginning of the trial. Anthropometrical parameters, such as body weight, waist circumference and BMI were collected both at the beginning and during the trial, together with hemodynamic and biochemical parameters. BMI was calculated as weight in kilograms divided by the square of height in meters. Hemodynamic parameters were collected measuring orthostatic and clinostatic systolic and diastolic blood pressure (mean value of 3 interval measures). Also orthostatic and clinostatic wrist blood pressure (mean value of 3 interval measures) and cardiac frequency were collected.</p><p>All biochemical parameters were obtained after a 12-h overnight fast. The following parameters were obtained or calculated through appropriate formulas: total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), TG, LDL-C, non-HDL cholesterol (non-HDL-C), FPG, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), creatinine, serum uric acid (SUA), liver transaminases [glutamic oxaloacetic transaminase (GOT); glutamate-pyruvate transaminase (GPT)], gamma glutamyl-transferase (&#x003b3;GT), and hsCRP [<xref ref-type="bibr" rid="CR18">18</xref>]. All measurements were centrally performed in the laboratory of our department with standardized methods [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>HOMA-IR is the simplest and most commonly used method to estimate insulin resistance. It was calculated as the product of basal glucose (mmol/L) and fasting insulin (U/mL) divided by 22.5 [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>Adherence to behavioural counselling and to treatment/placebo, tolerability, acceptability and compliance were also assessed.</p></sec><sec id="Sec6"><title>Statistical Analyses</title><p>Data have been analysed using intention to treat by mean of the Statistical Package for Social Science (SPSS) 21.0, version for Windows. Normally distributed baseline characteristics of the population have been compared using Student&#x02019;s <italic>t</italic> test, non-normally distributed parameters using Mann&#x02013;Whitney U test. Two-way analyses of variance for crossover design were used to assess the effect of treatment during the assumption of placebo or treatment. All data are expressed as means and standard deviation (SD). To verify the basic assumptions of crossover design, besides the evaluation of period effect, the presence of a carryover effect was excluded. Level of statistical significance was set on <italic>P</italic>&#x000a0;=&#x000a0;0.05.</p></sec></sec><sec id="Sec7"><title>Results</title><p>The main characteristics of the enrolled patients have been resumed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of the subjects enrolled in the trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">N. 30</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td char="." align="char">52.20</td><td char="." align="char">7.0</td></tr><tr><td align="left">Weight (kg)</td><td char="." align="char">80.6</td><td char="." align="char">7.5</td></tr><tr><td align="left">Body mass index (kg/m<sup>2</sup>)</td><td char="." align="char">26.7</td><td char="." align="char">1.8</td></tr><tr><td align="left">Waist circumference (cm)</td><td char="." align="char">99.8</td><td char="." align="char">7.6</td></tr><tr><td align="left">SBP (mmHg)</td><td char="." align="char">134.2</td><td char="." align="char">8.6</td></tr><tr><td align="left">DBP (mmHg)</td><td char="." align="char">80.4</td><td char="." align="char">3.4</td></tr><tr><td align="left">Pulse pressure (mmHg)</td><td char="." align="char">54.1</td><td char="." align="char">6.3</td></tr><tr><td align="left">MAP (mmHg)</td><td char="." align="char">97.5</td><td char="." align="char">7.5</td></tr><tr><td align="left">Heart rate (bpm)</td><td char="." align="char">72.4</td><td char="." align="char">4.4</td></tr><tr><td align="left">FPG (mg/dL)</td><td char="." align="char">106.9</td><td char="." align="char">4.9</td></tr><tr><td align="left">Insulin (&#x000b5;U/mL)</td><td char="." align="char">12.5</td><td char="." align="char">3.3</td></tr><tr><td align="left">HOMA-IR</td><td char="." align="char">3.4</td><td char="." align="char">0.8</td></tr><tr><td align="left">Total cholesterol (mg/dL)</td><td char="." align="char">248.7</td><td char="." align="char">14.3</td></tr><tr><td align="left">LDL-C (mg/dL)</td><td char="." align="char">165.2</td><td char="." align="char">13.2</td></tr><tr><td align="left">Triglycerides (mg/dL)</td><td char="." align="char">219.4</td><td char="." align="char">17.1</td></tr><tr><td align="left">HDL-C (mg/dL)</td><td char="." align="char">40.1</td><td char="." align="char">2.9</td></tr><tr><td align="left">Non HDL-C (mg/dL)</td><td char="." align="char">205.8</td><td char="." align="char">13.4</td></tr><tr><td align="left">GOT (U/L)</td><td char="." align="char">22.7</td><td char="." align="char">6.7</td></tr><tr><td align="left">GPT (U/L)</td><td char="." align="char">21.9</td><td char="." align="char">6.3</td></tr><tr><td align="left">Serum uric acid (mg/dL)</td><td char="." align="char">4.3</td><td char="." align="char">0.9</td></tr><tr><td align="left">Creatinine (mg/dL)</td><td char="." align="char">0.9</td><td char="." align="char">0.1</td></tr><tr><td align="left">hsCRP (mg/dL)</td><td char="." align="char">2.2</td><td char="." align="char">0.4</td></tr></tbody></table><table-wrap-foot><p>
<italic>SBP</italic> systolic blood pressure, <italic>DBP</italic> diastolic blood pressure, <italic>MAP</italic> mean arterial pressure, <italic>LDL</italic>-<italic>C</italic> LDL cholesterol, <italic>HDL</italic>-<italic>C</italic> HDL cholesterol, <italic>non HDL</italic>-<italic>C</italic> non HDL cholesterol, <italic>FPG</italic> fasting plasma glucose, <italic>HOMA</italic>-<italic>IR</italic> homeostatic model assessment of insulin resistance, <italic>GOT</italic> glutamic oxaloacetic transaminase, <italic>GPT</italic> glutamate-pyruvate transaminase, <italic>hsCRP</italic> high sensitivity C-reactive protein</p></table-wrap-foot></table-wrap>
</p><p>At the baseline, the two treatment sequence groups were balanced for all the investigated parameters. All the patients completed the study and no one experienced adverse events during the trial.</p><p>Compared to baseline values, no change has been observed after both treatments as it regards Body weight, body mass index, waist circumference, diastolic blood pressure (DBP), pulse pressure (PP), heart rate (HR), creatinine and SUA level (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Mean difference in changes of the studied parameters after placebo or nutraceutical treatment (*P&#x000a0;&#x0003c;&#x000a0;0.05 nutraceutical vs. placebo)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">N. 30</th><th align="left" colspan="4">After nutraceutical treatment</th><th align="left" colspan="4">After placebo treatment</th></tr><tr><th align="left" rowspan="2">Mean difference in changes</th><th align="left" colspan="2">95&#x000a0;% CI</th><th align="left" rowspan="2">P</th><th align="left" rowspan="2">Mean difference in changes</th><th align="left" colspan="2">95&#x000a0;% CI</th><th align="left" rowspan="2">P</th></tr><tr><th align="left">Lower</th><th align="left">Upper</th><th align="left">Lower</th><th align="left">Upper</th></tr></thead><tbody><tr><td align="left">&#x00394;Weight (kg)</td><td char="." align="char">&#x02212;0.2</td><td char="." align="char">&#x02212;0.7</td><td char="." align="char">1.0</td><td char="." align="char">0.621</td><td char="." align="char">&#x02212;0.3</td><td char="." align="char">&#x02212;0.9</td><td char="." align="char">0.8</td><td char="." align="char">0.798</td></tr><tr><td align="left">&#x00394;BMI (kg/m<sup>2</sup>)</td><td char="." align="char">&#x02212;0.1</td><td char="." align="char">&#x02212;0.6</td><td char="." align="char">0.9</td><td char="." align="char">0.712</td><td char="." align="char">&#x02212;0.1</td><td char="." align="char">&#x02212;0.4</td><td char="." align="char">0.7</td><td char="." align="char">0.684</td></tr><tr><td align="left">&#x00394;WC (cm)</td><td char="." align="char">&#x02212;0.5</td><td char="." align="char">&#x02212;1.0</td><td char="." align="char">0.8</td><td char="." align="char">0.498</td><td char="." align="char">&#x02212;0.3</td><td char="." align="char">&#x02212;1.1</td><td char="." align="char">0.8</td><td char="." align="char">0.437</td></tr><tr><td align="left">&#x00394;SBP (mmHg)</td><td char="." align="char">&#x02212;1.7</td><td char="." align="char">&#x02212;3.7</td><td char="." align="char">1.2</td><td char="." align="char">0.291</td><td char="." align="char">&#x02212;1.2</td><td char="." align="char">&#x02212;3.4</td><td char="." align="char">1.1</td><td char="." align="char">0.358</td></tr><tr><td align="left">&#x00394;DBP (mmHg)</td><td char="." align="char">&#x02212;0.9</td><td char="." align="char">&#x02212;2.6</td><td char="." align="char">0.3</td><td char="." align="char">0.092</td><td char="." align="char">&#x02212;0.6</td><td char="." align="char">&#x02212;2.1</td><td char="." align="char">0.5</td><td char="." align="char">0.275</td></tr><tr><td align="left">&#x00394;PP (mmHg)</td><td char="." align="char">&#x02212;0.8</td><td char="." align="char">&#x02212;1.9</td><td char="." align="char">0.2</td><td char="." align="char">0.084</td><td char="." align="char">&#x02212;0.6</td><td char="." align="char">&#x02212;1.3</td><td char="." align="char">0.7</td><td char="." align="char">0.139</td></tr><tr><td align="left">&#x00394;MAP (mmHg)</td><td char="." align="char">&#x02212;1.2</td><td char="." align="char">&#x02212;2.2</td><td char="." align="char">0.9</td><td char="." align="char">0.192</td><td char="." align="char">&#x02212;0.9</td><td char="." align="char">&#x02212;1.6</td><td char="." align="char">0.6</td><td char="." align="char">0.121</td></tr><tr><td align="left">&#x00394;HR (bpm)</td><td char="." align="char">1.4</td><td char="." align="char">&#x02212;2.3</td><td char="." align="char">6.6</td><td char="." align="char">0.544</td><td char="." align="char">&#x02212;2.1</td><td char="." align="char">&#x02212;2.9</td><td char="." align="char">3.4</td><td char="." align="char">0.484</td></tr><tr><td align="left">&#x00394;TC (mg/dL)</td><td char="." align="char">&#x02212;34.1</td><td char="." align="char">&#x02212;56.8</td><td char="." align="char">&#x02212;11.3</td><td char="." align="char">&#x0003c;0.001*</td><td char="." align="char">&#x02212;10.1</td><td char="." align="char">&#x02212;18.3</td><td char="." align="char">5.6</td><td char="." align="char">0.060</td></tr><tr><td align="left">&#x00394;LDL-C (mg/dL)</td><td char="." align="char">&#x02212;30.3</td><td char="." align="char">&#x02212;49.7</td><td char="." align="char">&#x02212;7.4</td><td char="." align="char">&#x0003c;0.001*</td><td char="." align="char">&#x02212;8.4</td><td char="." align="char">&#x02212;16.5</td><td char="." align="char">4.8</td><td char="." align="char">0.064</td></tr><tr><td align="left">&#x00394;Triglycerides (mg/dL)</td><td char="." align="char">&#x02212;19.8</td><td char="." align="char">&#x02212;44.8</td><td char="." align="char">&#x02212;9.2</td><td char="." align="char">&#x0003c;0.001*</td><td char="." align="char">&#x02212;11.4</td><td char="." align="char">&#x02212;25.6</td><td char="." align="char">2.5</td><td char="." align="char">0.051</td></tr><tr><td align="left">&#x00394;HDL-C (mg/dL)</td><td char="." align="char">0.4</td><td char="." align="char">&#x02212;0.6</td><td char="." align="char">1.3</td><td char="." align="char">0.084</td><td char="." align="char">0.3</td><td char="." align="char">&#x02212;0.9</td><td char="." align="char">0.5</td><td char="." align="char">0.349</td></tr><tr><td align="left">&#x00394;Non HDL-C (mg/dL)</td><td char="." align="char">&#x02212;31.2</td><td char="." align="char">&#x02212;45.5</td><td char="." align="char">&#x02212;8.1</td><td char="." align="char">&#x0003c;0.001*</td><td char="." align="char">&#x02212;9.5</td><td char="." align="char">&#x02212;17.2</td><td char="." align="char">5.0</td><td char="." align="char">0.062</td></tr><tr><td align="left">&#x00394;FPG (mg/dL)</td><td char="." align="char">&#x02212;5.1</td><td char="." align="char">&#x02212;9.4</td><td char="." align="char">4.6</td><td char="." align="char">0.239</td><td char="." align="char">&#x02212;3.9</td><td char="." align="char">&#x02212;8.7</td><td char="." align="char">6.6</td><td char="." align="char">0.486</td></tr><tr><td align="left">&#x00394;Insulin (&#x000b5;U/mL)</td><td char="." align="char">&#x02212;1.2</td><td char="." align="char">&#x02212;1.9</td><td char="." align="char">0.1</td><td char="." align="char">0.068</td><td char="." align="char">&#x02212;0.5</td><td char="." align="char">&#x02212;1.7</td><td char="." align="char">0.8</td><td char="." align="char">0.537</td></tr><tr><td align="left">&#x00394;HOMA-IR</td><td char="." align="char">&#x02212;0.5</td><td char="." align="char">&#x02212;0.7</td><td char="." align="char">0.2</td><td char="." align="char">0.091</td><td char="." align="char">&#x02212;0.1</td><td char="." align="char">&#x02212;0.6</td><td char="." align="char">0.4</td><td char="." align="char">0.632</td></tr><tr><td align="left">&#x00394;GOT (U/L)</td><td char="." align="char">&#x02212;2.3</td><td char="." align="char">&#x02212;5.7</td><td char="." align="char">&#x02212;0.9</td><td char="." align="char">0.024*</td><td char="." align="char">0.3</td><td char="." align="char">&#x02212;5.9</td><td char="." align="char">8.5</td><td char="." align="char">0.734</td></tr><tr><td align="left">&#x00394;GPT (U/L)</td><td char="." align="char">&#x02212;6.8</td><td char="." align="char">&#x02212;10.4</td><td char="." align="char">&#x02212;1.4</td><td char="." align="char">0.011*</td><td char="." align="char">2.9</td><td char="." align="char">&#x02212;4.1</td><td char="." align="char">7.6</td><td char="." align="char">0.533</td></tr><tr><td align="left">&#x00394;SUA (mg/dL)</td><td char="." align="char">&#x02212;1.4</td><td char="." align="char">&#x02212;2.7</td><td char="." align="char">1.2</td><td char="." align="char">0.432</td><td char="." align="char">&#x02212;0.4</td><td char="." align="char">&#x02212;2.9</td><td char="." align="char">2.4</td><td char="." align="char">0.883</td></tr><tr><td align="left">&#x00394;Creatinine (mg/dL)</td><td char="." align="char">&#x02212;0.2</td><td char="." align="char">&#x02212;0.5</td><td char="." align="char">0.8</td><td char="." align="char">0.547</td><td char="." align="char">0.2</td><td char="." align="char">&#x02212;0.3</td><td char="." align="char">0.5</td><td char="." align="char">0.638</td></tr><tr><td align="left">&#x00394;hsCRP</td><td char="." align="char">&#x02212;0.4</td><td char="." align="char">&#x02212;0.9</td><td char="." align="char">&#x02212;0.1</td><td char="." align="char">0.019*</td><td char="." align="char">0.1</td><td char="." align="char">&#x02212;0.3</td><td char="." align="char">0.6</td><td char="." align="char">0.348</td></tr></tbody></table><table-wrap-foot><p>
<italic>BMI</italic> body mass index, <italic>DBP</italic> diastolic blood pressure, <italic>FPG</italic> fasting plasma glucose, <italic>GOT</italic> glutamic oxaloacetic transaminase, <italic>GPT</italic> glutamate-pyruvate transaminase, <italic>HDL</italic>-<italic>C</italic> HDL cholesterol, <italic>HOMA</italic>-<italic>IR</italic> homeostatic model assessment of insulin resistance, <italic>HR</italic> heart rate, <italic>hsCRP</italic> high sensitivity C-reactive protein, <italic>LDL</italic>-<italic>C</italic> LDL cholesterol, <italic>non HDL</italic>-<italic>C</italic> non HDL cholesterol, <italic>MAP</italic> mean arterial pressure, <italic>PP</italic> pulse pressure, <italic>SBP</italic> systolic blood pressure, <italic>SUA</italic> serum uric acid, <italic>TC</italic> total cholesterol, <italic>WC</italic> waist circumference</p></table-wrap-foot></table-wrap>
</p><p>On the other hand, significant improvements have been reported in lipid, hepatic and inflammatory parameters in the active group versus placebo. In particular, there have been a mean reduction of total cholesterol of &#x02212;34.1&#x000a0;mg/dL (&#x02212;56.8; &#x02212;11.3&#x000a0;mg/dL; P&#x000a0;&#x0003c;&#x000a0;0.001), LDL-cholesterol of &#x02212;30.3&#x000a0;mg/dL (&#x02212;49.7; &#x02212;7.4; P&#x000a0;&#x0003c;&#x000a0;0.001), non-HDL cholesterol of &#x02212;31.2&#x000a0;mg/dL (&#x02212;45.5; &#x02212;8.1; P&#x000a0;&#x0003c;&#x000a0;0.001), GOT of &#x02212;2.3 U/L (&#x02212;5.7; &#x02212;0.9; P&#x000a0;&#x0003c;&#x000a0;0.024), GPT of &#x02212;6.8&#x000a0;U/L (&#x02212;10.4; &#x02212;1.4; P&#x000a0;&#x0003c;&#x000a0;0.011), hs-CRP of &#x02212;0.4 (&#x02212;0.9; &#x02212;0.1; P&#x000a0;&#x0003c;&#x000a0;0.019).</p><p>Fasting plasma glucose and insulin levels also mildly improved in the nutraceutical group, but the observed changes did not reach the statistical significance.</p></sec><sec id="Sec8"><title>Discussion</title><p>The increase of the average age and the quality of life has caused a raise of cardiovascular diseases in the developed countries, that cannot be contained only with an improvement of lifestyle and the use of drugs, either in terms of costs either of the management of potential side effects [<xref ref-type="bibr" rid="CR21">21</xref>]. In fact, even though the improvement in its treatment, cardiovascular diseases remain the first cause of death in the developed countries and it is increasingly necessary a widespread prevention [<xref ref-type="bibr" rid="CR22">22</xref>]. So, it is important to treat its principle risk factors, since they reach borderline values. Considering that patients must be divided into low, medium and high cardiovascular risk, the primary approach for the first category consists in a change of dietary habits and physical activity [<xref ref-type="bibr" rid="CR23">23</xref>]. Nevertheless, the improvement of lifestyle is often not enough to get the parameters in the optimal range, while, in these patients, the use of drugs can be excessive and give avoidable side effects. The use of nutraceuticals has demonstrated to be a useful tool, because of its safety, high tolerability and the opportunity to treat more risk factors with only one poly-pill.</p><p>In literature, banaba, red yeast rice, artichoke and coenzyme Q10 have been tested mainly alone [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>] or in association towards only one risk factor. For example, artichoke leaf extract and red yeast rice have been studied in their synergic effect on lipid metabolism [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p>In this clinical trial, the lipid-lowering properties of red yeast rice, the hypoglicemic effects of banaba together with the choleretic, hepatoprotective and bile-enhancing effects of artichoke and the antioxidant activity of coenzyme Q10 have been studied together and have demonstrated to be synergic. The results in fact have shown their effectiveness on lipid metabolism, hepatic and inflammatory parameters and the improvement of glucose metabolism in hypercholesterolemic patients. In particular, the after the nutraceutical treatment the enrolled patients experienced a significant improvement in TC (&#x02212;13.6&#x000a0;%), LDL-C (&#x02212;18.2&#x000a0;%), non-HDL-C (&#x02212;15&#x000a0;%), GOT (&#x02212;10&#x000a0;%), GPT (&#x02212;30.9&#x000a0;%), and hs-CRP (&#x02212;18.2&#x000a0;%). The results are in line with what expected from previous trials carried out on the individual components [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], but achieved with a single administration per day of more nutraceuticals combined in a tablet. Of particular interest, is the improvement of liver transaminases, both because usually the increase of transaminases is a common feature with lipid-lowering therapy [<xref ref-type="bibr" rid="CR31">31</xref>], and because high transaminases could be a marker of liver steatosis, that seems to be per se an emerging risk factor for cardiovascular disease [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Nevertheless, our trial has some limitation. The first one is the relatively small sample size, partially balanced by the cross-over design of the trial. The second one is the relatively short duration of the trial, however comparable with the most part of explorative trials carried out with metabolically active nutraceuticals. Then, we have not prescribed a specific diet based on bromatological data, but we gave only general dietary suggestion finalized at avoiding dietary excess in order to simulate more strictly a condition of general practice.</p></sec><sec id="Sec08"><title>Conclusions</title><p>In our clinical trial, the use of combined nutraceuticals has demonstrated to be well tolerated in hypercholesterolemic patients and has shown to be effective in the simultaneous improvement of more risk factors: dyslipidaemia, liver transaminases and hsCRP. These results have to be confirmed in larger and longer trials.</p></sec></body><back><ack><p>This work has been carried out with institutional funding from the University of Bologna, Italy.</p></ack><notes notes-type="COI-statement"><title>Compliance with Ethical Standards</title><sec id="FPar1"><title>Conflict of interest</title><p>The authors declare that they have no conflict of interest.</p></sec><sec id="d29e1535"><title>Research involving human participants and/or animals</title><p>This article does not contain any studies with human participants or animals performed by any of the authors.</p></sec><sec id="d29e1540"><title>Informed Consent</title><p>For this study informed consent is not required.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Hawken</surname><given-names>S</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><name><surname>Dans</surname><given-names>T</given-names></name><name><surname>Avezum</surname><given-names>A</given-names></name><name><surname>Lanas</surname><given-names>F</given-names></name><name><surname>McQueen</surname><given-names>M</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><name><surname>Pais</surname><given-names>P</given-names></name><name><surname>Varigos</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study</article-title><source>Lancet</source><year>2004</year><volume>364</volume><fpage>937</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)17018-9</pub-id><pub-id pub-id-type="pmid">15364185</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrani</surname><given-names>AD</given-names></name><name><surname>Adesiyun</surname><given-names>T</given-names></name><name><surname>Quispe</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>SR</given-names></name><name><surname>Stone</surname><given-names>NJ</given-names></name><name><surname>Blumenthal</surname><given-names>RS</given-names></name><name><surname>Martin</surname><given-names>SS</given-names></name></person-group><article-title>Dyslipidemia&#x000a0;management in primary prevention of&#x000a0;cardiovascular&#x000a0;disease: Current guidelines and strategies</article-title><source>World J Cardiol.</source><year>2016</year><volume>8</volume><issue>2</issue><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.4330/wjc.v8.i2.201</pub-id><pub-id pub-id-type="pmid">26981215</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatine</surname><given-names>MS</given-names></name></person-group><article-title>Advances in the treatment of&#x000a0;dyslipidemia</article-title><source>Cleve Clin J Med.</source><year>2016</year><volume>83</volume><issue>3</issue><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.3949/ccjm.83gr.16001</pub-id><pub-id pub-id-type="pmid">26974988</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannarino</surname><given-names>MR</given-names></name><name><surname>Ministrini</surname><given-names>S</given-names></name><name><surname>Pirro</surname><given-names>M</given-names></name></person-group><article-title>Nutraceuticals for the treatment of hypercholesterolemia</article-title><source>Eur J Intern Med.</source><year>2014</year><volume>25</volume><issue>7</issue><fpage>592</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/j.ejim.2014.06.008</pub-id><pub-id pub-id-type="pmid">24997485</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>FM</given-names></name></person-group><article-title>Red yeast rice&#x000a0;for the treatment of&#x000a0;dyslipidemia</article-title><source>Curr Atheroscler Rep.</source><year>2015</year><volume>17</volume><issue>4</issue><fpage>495</fpage><pub-id pub-id-type="doi">10.1007/s11883-015-0495-8</pub-id><pub-id pub-id-type="pmid">25728312</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Wider B, Pittler MH, Thompson-Coon J, Ernst E. Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev. 2013;3:CD003335.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupattelli</surname><given-names>G</given-names></name><name><surname>Marchesi</surname><given-names>S</given-names></name><name><surname>Lombardini</surname><given-names>R</given-names></name><name><surname>Roscini</surname><given-names>AR</given-names></name><name><surname>Trinca</surname><given-names>F</given-names></name><name><surname>Gemelli</surname><given-names>F</given-names></name><name><surname>Vaudo</surname><given-names>G</given-names></name><name><surname>Mannarino</surname><given-names>E</given-names></name></person-group><article-title>Artichoke juice improves endothelial function in hyperlipemia</article-title><source>Life Sci</source><year>2004</year><volume>76</volume><issue>7</issue><fpage>775</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2004.07.018</pub-id><pub-id pub-id-type="pmid">15581909</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Salem</surname><given-names>M</given-names></name><name><surname>Affes</surname><given-names>H</given-names></name><name><surname>Ksouda</surname><given-names>K</given-names></name><name><surname>Dhouibi</surname><given-names>R</given-names></name><name><surname>Sahnoun</surname><given-names>Z</given-names></name><name><surname>Hammami</surname><given-names>S</given-names></name><name><surname>Zeghal</surname><given-names>KM</given-names></name></person-group><article-title>Pharmacological studies of Artichoke leaf extract and their health benefits</article-title><source>Plant Foods Hum Nutr</source><year>2015</year><volume>70</volume><issue>4</issue><fpage>441</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1007/s11130-015-0503-8</pub-id><pub-id pub-id-type="pmid">26310198</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rondanelli</surname><given-names>M</given-names></name><name><surname>Monteferrario</surname><given-names>F</given-names></name><name><surname>Perna</surname><given-names>S</given-names></name><name><surname>Faliva</surname><given-names>MA</given-names></name><name><surname>Opizzi</surname><given-names>A</given-names></name></person-group><article-title>Health-promoting properties of&#x000a0;artichoke&#x000a0;in preventing cardiovascular disease by its lipidic and glycemic-reducing action</article-title><source>Monaldi Arch Chest Dis</source><year>2013</year><volume>80</volume><issue>1</issue><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">23923586</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Himmeldirk</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa</article-title><source>Evid Based Complement Alternat Med.</source><year>2007</year><volume>4</volume><issue>4</issue><fpage>401</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1093/ecam/nem013</pub-id><pub-id pub-id-type="pmid">18227906</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stohs</surname><given-names>SJ</given-names></name><name><surname>Miller</surname><given-names>H</given-names></name><name><surname>Kaats</surname><given-names>GR</given-names></name></person-group><article-title>A review of the efficacy and safety of&#x000a0;banaba&#x000a0;(Lagerstroemia speciosa L.) and corosolic acid</article-title><source>Phytother Res</source><year>2012</year><volume>26</volume><issue>3</issue><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">22095937</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Cicero AF, Colletti A. Role of phytochemicals in the management of metabolic syndrome. Phytomedicine. 2015 Dec 11. doi:10.1016/j.phymed.2015.11.009.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido-Maraver</surname><given-names>J</given-names></name><name><surname>Cordero</surname><given-names>MD</given-names></name><name><surname>Oropesa-Avila</surname><given-names>M</given-names></name><name><surname>Vega</surname><given-names>AF</given-names></name><name><surname>de la Mata</surname><given-names>M</given-names></name><name><surname>Pavon</surname><given-names>AD</given-names></name><name><surname>Alcocer-Gomez</surname><given-names>E</given-names></name><name><surname>Calero</surname><given-names>CP</given-names></name><name><surname>Paz</surname><given-names>MV</given-names></name><name><surname>Alanis</surname><given-names>M</given-names></name><name><surname>de Lavera</surname><given-names>I</given-names></name><name><surname>Cotan</surname><given-names>D</given-names></name><name><surname>Sanchez-Alcazar</surname><given-names>JA</given-names></name></person-group><article-title>Clinical applications of coenzyme Q10</article-title><source>Front Biosci.</source><year>2014</year><volume>19</volume><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.2741/4231</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>H</given-names></name><name><surname>Devi</surname><given-names>P</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name></person-group><article-title>Role of&#x000a0;coenzyme Q10&#x000a0;(CoQ10) in cardiac disease, hypertension and Meniere-like syndrome</article-title><source>Pharmacol Ther</source><year>2009</year><volume>124</volume><issue>3</issue><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2009.07.003</pub-id><pub-id pub-id-type="pmid">19638284</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarter</surname><given-names>B</given-names></name></person-group><article-title>Coenzyme Q10&#x000a0;and&#x000a0;cardiovascular&#x000a0;disease: a review</article-title><source>J Cardiovasc Nurs</source><year>2002</year><volume>16</volume><issue>4</issue><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1097/00005082-200207000-00003</pub-id><pub-id pub-id-type="pmid">12597259</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Cicero AF, Colletti A. Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data. Phytomedicine. 2015 Nov 10. doi:10.1016/j.phymed.2015.10.011.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpe</surname><given-names>R</given-names></name><name><surname>Sotis</surname><given-names>G</given-names></name></person-group><article-title>Nutraceuticals: definition and epidemiological rationale for their use in clinical practice</article-title><source>High Blood Press Cardiovasc Prev.</source><year>2015</year><volume>22</volume><issue>3</issue><fpage>199</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1007/s40292-015-0092-5</pub-id><pub-id pub-id-type="pmid">25929684</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>AF</given-names></name><name><surname>Morbini</surname><given-names>M</given-names></name><name><surname>Rosticci</surname><given-names>M</given-names></name><name><surname>D&#x02019;&#x02019;Addato</surname><given-names>S</given-names></name><name><surname>Grandi</surname><given-names>E</given-names></name><name><surname>Borghi</surname><given-names>C</given-names></name></person-group><article-title>Middle-term dietary supplementation with red yeast rice plus coenzyme Q10 improves lipid pattern, endothelial reactivity and arterial stiffness in moderately hypercholesterolemic subjects</article-title><source>Ann Nutr Metab </source><year>2016</year><volume>68</volume><issue>3</issue><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1159/000445359</pub-id><pub-id pub-id-type="pmid">27055107</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>AF</given-names></name><name><surname>Rosticci</surname><given-names>M</given-names></name><name><surname>Reggi</surname><given-names>A</given-names></name><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Parini</surname><given-names>A</given-names></name><name><surname>Grandi</surname><given-names>E</given-names></name><name><surname>D&#x02019;Addato</surname><given-names>S</given-names></name><name><surname>Borghi</surname><given-names>C</given-names></name></person-group><article-title>Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study</article-title><source>High Blood Press Cardiovasc Prev.</source><year>2015</year><volume>22</volume><issue>2</issue><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/s40292-014-0077-9</pub-id><pub-id pub-id-type="pmid">25512187</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/BF00280883</pub-id><pub-id pub-id-type="pmid">3899825</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borghi</surname><given-names>C</given-names></name><name><surname>Cicero</surname><given-names>AF</given-names></name></person-group><article-title>Nutraceuticals with clinically detectable blood pressure lowering effect: a review of available randomized clinical trials and their meta-analyses</article-title><source>Br J Clin Pharmacol</source><year>2016</year><pub-id pub-id-type="pmid">26852373</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banegas</surname><given-names>JR</given-names></name><name><surname>L&#x000f3;pez-Garc&#x000ed;a</surname><given-names>E</given-names></name><name><surname>Dallongeville</surname><given-names>J</given-names></name><name><surname>Guallar</surname><given-names>E</given-names></name><name><surname>Halcox</surname><given-names>JP</given-names></name><name><surname>Borghi</surname><given-names>C</given-names></name><name><surname>Mass&#x000f3;-Gonz&#x000e1;lez</surname><given-names>EL</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>FJ</given-names></name><name><surname>Perk</surname><given-names>J</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Rodr&#x000ed;guez-Artalejo</surname><given-names>F</given-names></name></person-group><article-title>Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>2143</fpage><lpage>2152</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr080</pub-id><pub-id pub-id-type="pmid">21471134</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>S</given-names></name><name><surname>Gerdtham</surname><given-names>UG</given-names></name><name><surname>Johansson</surname><given-names>P</given-names></name></person-group><article-title>Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases</article-title><source>Int J Environ Res Public Health</source><year>2010</year><volume>7</volume><fpage>3150</fpage><lpage>3195</lpage><pub-id pub-id-type="doi">10.3390/ijerph7083150</pub-id><pub-id pub-id-type="pmid">20948954</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name></person-group><article-title>Management of diabetes and its complications with banaba (<italic>Lagerstroemia speciosa</italic> L.) and Corosolic Acid</article-title><source>Evid Based Complement Alternat Med.</source><year>2012</year><volume>2012</volume><fpage>871495</fpage><pub-id pub-id-type="doi">10.1155/2012/871495</pub-id><pub-id pub-id-type="pmid">23082086</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>AF</given-names></name><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Parini</surname><given-names>A</given-names></name><name><surname>Maffioli</surname><given-names>P</given-names></name><name><surname>D&#x02019;Addato</surname><given-names>S</given-names></name><name><surname>Reggi</surname><given-names>A</given-names></name><name><surname>Giovannini</surname><given-names>M</given-names></name><name><surname>Borghi</surname><given-names>C</given-names></name></person-group><article-title>Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects</article-title><source>Nutr Res.</source><year>2013</year><volume>33</volume><issue>8</issue><fpage>622</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2013.05.015</pub-id><pub-id pub-id-type="pmid">23890351</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rondanelli</surname><given-names>M</given-names></name><name><surname>Giacosa</surname><given-names>A</given-names></name><name><surname>Opizzi</surname><given-names>A</given-names></name><name><surname>Faliva</surname><given-names>MA</given-names></name><name><surname>Sala</surname><given-names>P</given-names></name><name><surname>Perna</surname><given-names>S</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name><name><surname>Morazzoni</surname><given-names>P</given-names></name><name><surname>Bombardelli</surname><given-names>E</given-names></name></person-group><article-title>Beneficial effects of artichoke leaf extract supplementation on increasing HDL-cholesterol in subjects with primary mild hypercholesterolaemia: a double-blind, randomized, placebo-controlled trial</article-title><source>Int J Food Sci Nutr</source><year>2013</year><volume>64</volume><issue>1</issue><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.3109/09637486.2012.700920</pub-id><pub-id pub-id-type="pmid">22746542</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidaka</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Funahashi</surname><given-names>I</given-names></name><name><surname>Fukutomi</surname><given-names>N</given-names></name><name><surname>Hosoe</surname><given-names>K</given-names></name></person-group><article-title>Safety assessment of coenzyme Q10 (CoQ10)</article-title><source>BioFactors</source><year>2008</year><volume>32</volume><issue>1&#x02013;4</issue><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1002/biof.5520320124</pub-id><pub-id pub-id-type="pmid">19096117</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrat</surname><given-names>E</given-names></name><name><surname>Za&#x000ef;r</surname><given-names>Y</given-names></name><name><surname>Sirvent</surname><given-names>P</given-names></name><name><surname>Chauveau</surname><given-names>P</given-names></name><name><surname>Maudet</surname><given-names>C</given-names></name><name><surname>Housez</surname><given-names>B</given-names></name><name><surname>Derbord</surname><given-names>E</given-names></name><name><surname>Lescuyer</surname><given-names>JF</given-names></name><name><surname>Bard</surname><given-names>JM</given-names></name><name><surname>Cazaubiel</surname><given-names>M</given-names></name><name><surname>Peltier</surname><given-names>SL</given-names></name></person-group><article-title>Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study</article-title><source>Eur J Nutr</source><year>2013</year><volume>52</volume><issue>8</issue><fpage>1843</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1007/s00394-012-0486-2</pub-id><pub-id pub-id-type="pmid">23266743</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>AF</given-names></name><name><surname>Tartagni</surname><given-names>E</given-names></name><name><surname>Ertek</surname><given-names>S</given-names></name></person-group><article-title>Nutraceuticals for metabolic syndrome management: from laboratory to benchside</article-title><source>Curr Vasc Pharmacol</source><year>2014</year><volume>12</volume><issue>4</issue><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.2174/15701611113119990120</pub-id><pub-id pub-id-type="pmid">23627983</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicero</surname><given-names>AF</given-names></name><name><surname>Ferroni</surname><given-names>A</given-names></name><name><surname>Ertek</surname><given-names>S</given-names></name></person-group><article-title>Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects</article-title><source>Expert Opin Drug Saf.</source><year>2012</year><volume>11</volume><issue>5</issue><fpage>753</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1517/14740338.2012.705827</pub-id><pub-id pub-id-type="pmid">22788832</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>CS</given-names></name><name><surname>Martin</surname><given-names>SS</given-names></name><name><surname>Blumenthal</surname><given-names>RS</given-names></name></person-group><article-title>Non-cardiovascular effects associated with statins</article-title><source>BMJ</source><year>2014</year><volume>349</volume><fpage>g3743</fpage><pub-id pub-id-type="doi">10.1136/bmj.g3743</pub-id><pub-id pub-id-type="pmid">25035309</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016 Apr 15. doi:10.1016/j.jhep.2016.04.005.</mixed-citation></ref></ref-list></back></article>